US20100233304A1 - Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions - Google Patents

Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions Download PDF

Info

Publication number
US20100233304A1
US20100233304A1 US12/734,013 US73401308A US2010233304A1 US 20100233304 A1 US20100233304 A1 US 20100233304A1 US 73401308 A US73401308 A US 73401308A US 2010233304 A1 US2010233304 A1 US 2010233304A1
Authority
US
United States
Prior art keywords
canceled
animal
composition
compositions
norc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/734,013
Other languages
English (en)
Inventor
Yuanlong Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100233304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Priority to US12/734,013 priority Critical patent/US20100233304A1/en
Publication of US20100233304A1 publication Critical patent/US20100233304A1/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PAN, YUANLONG
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the food compositions comprise any of a variety of ingredients or combinations thereof selected for their contributions to the overall composition.
  • a skilled food technologist may choose from among natural (e.g., plant or plant-derived, animal, or animal-derived, and microbial or microbially-derived), and synthetic ingredients or components.
  • the ingredients may include any of the cereal grains and/or fractions or components thereof, meat and meat by-products, fish, shellfish, or other seafood, other animal products or by-products, eggs from any source, vitamins, minerals, salts, sweeteners, fiber, flavoring or other palatants, coloring, and functional ingredients such as emulsifiers, stabilizers, softeners, functional coatings, and the like.
  • the composition is formulated to provide about 0.5 g to about 10 g each of UFA and NORC per day in one or more portions of a recommended serving size.
  • a 10 g dose can be provided by formulating the composition such that each recommended portion (e.g., 2 spoonsful, or one 20 g portion, or the like) to provide 5 g each of UFA and NORC.
  • ornithine is a precursor to L-arginine.
  • ornithine can substitute for L-arginine in nutritional compositions.
  • ornithine is not metabolized by the liver following entry into the bloodstream through absorption from the diet or de novo intestinal production.
  • Ornithine is enzymatically converted to arginine by mitochondria via a part of the urea cycle.
  • Administration in accordance with the methods can be on an as-needed or as-desired basis of varying or regular frequency.
  • a goal of regular ingestion is to provide the animal with a regular and consistent dose of the composition or the direct or indirect metabolites that result from such ingestion. Such regular and consistent dosing will tend to create constant blood levels of the components of the compositions or their direct or indirect metabolites.
  • regular administration can be once monthly, once weekly, once daily, or more than once daily.
  • administration can be every other day, week, or month, every third day, week, or month, every fourth day, week, or month, and the like. Administration can be multiple times per day.
  • the UFA is a fish oil and the NORC is arginine or a nitric oxide-releasing derivative thereof.
  • the invention provides methods for preventing or treating strokes in an animal.
  • the methods comprise administering a composition comprising UFA and NORC to the animal in an amount effective to prevent or treat strokes.
  • the compositions further comprise one or more B vitamins, one or more antioxidants, or both in amounts effective for preventing or treating strokes in an animal.
  • the methods are based upon the discovery that reducing damage that results from strokes is correlated to certain aspects of enhancing cognitive function, e.g., reducing memory loss.
  • compositions can be made according to any method suitable in the art.
  • mice Male Charles Rivers Sprague-Dawley rats (250 g, Wilmington, Mass.) were acclimatized to animal facilities 3 days prior to surgery with a 12 hour light-dark cycle. Bilateral ovariectomy was performed 2 weeks before diet feeding began. Four weeks after the start of diet feeding, transient middle cerebral artery (tMCA) occlusion under anesthesia was performed following intraperitoneal injection of ketamine (60 mgkg) and xylazine (10 mg/kg). 15 rats per group were randomly assigned to one of four treatment groups:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
US12/734,013 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions Abandoned US20100233304A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/734,013 US20100233304A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1009708P 2008-01-04 2008-01-04
US13738208P 2008-07-30 2008-07-30
PCT/US2008/013870 WO2009088433A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
US12/734,013 US20100233304A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013870 A-371-Of-International WO2009088433A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/440,702 Continuation-In-Part US10111911B2 (en) 2008-01-04 2017-02-23 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Publications (1)

Publication Number Publication Date
US20100233304A1 true US20100233304A1 (en) 2010-09-16

Family

ID=40853324

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/734,013 Abandoned US20100233304A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US15/440,702 Active 2029-02-06 US10111911B2 (en) 2008-01-04 2017-02-23 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US16/150,979 Active US10973859B2 (en) 2008-01-04 2018-10-03 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US17/206,851 Active 2030-06-19 US11951137B2 (en) 2008-01-04 2021-03-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/440,702 Active 2029-02-06 US10111911B2 (en) 2008-01-04 2017-02-23 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US16/150,979 Active US10973859B2 (en) 2008-01-04 2018-10-03 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US17/206,851 Active 2030-06-19 US11951137B2 (en) 2008-01-04 2021-03-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Country Status (11)

Country Link
US (4) US20100233304A1 (pt)
EP (2) EP2224930B1 (pt)
JP (1) JP5979816B2 (pt)
CN (2) CN105267969A (pt)
AU (1) AU2008347177B2 (pt)
BR (1) BRPI0822238B8 (pt)
CA (2) CA2994586C (pt)
ES (2) ES2773928T5 (pt)
MX (1) MX337760B (pt)
RU (1) RU2500402C2 (pt)
WO (1) WO2009088433A1 (pt)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292330A1 (en) * 2007-10-04 2010-11-18 Yuanlong Pan Compositions and methods for enhancing cognitive function
WO2012103049A1 (en) 2011-01-25 2012-08-02 Nestec S. A. Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
WO2012112340A2 (en) * 2011-02-18 2012-08-23 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
AT511776A1 (de) * 2011-07-26 2013-02-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US20140004205A1 (en) * 2011-03-18 2014-01-02 Nestec Sa Compositions and methods useful for ameliorating age related maladies
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US20150265670A1 (en) * 2012-10-30 2015-09-24 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US10201513B2 (en) 2016-12-19 2019-02-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10660870B2 (en) 2017-08-14 2020-05-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US11311581B2 (en) * 2014-10-22 2022-04-26 Again Life Italia Srl Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CN102170792A (zh) * 2008-07-18 2011-08-31 希尔氏宠物营养品公司 提高老龄动物生活质量的方法
AU2013200758B2 (en) * 2008-07-18 2014-06-12 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
RU2569743C2 (ru) * 2009-09-11 2015-11-27 Нестек С.А. Композиции и способы усиления когнитивной функции и связанных с ней функций у животных
SG181975A1 (en) * 2009-12-29 2012-08-30 Nestec Sa Nutritional compositions comprising fruit flakes containing docosahexaenoic acid
CN102552457A (zh) * 2010-12-24 2012-07-11 漆又毛 一种氨基酸和提取物组合物的药物用途
US20130059028A1 (en) * 2011-09-01 2013-03-07 Julie Marie Foy Compositions and Methods for Providing a Life-Stage-Appropriate Animal Diet
CN102600124B (zh) * 2012-02-06 2014-03-26 单宝华 Omega-3增强组合物及其应用
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
EP3074767A1 (en) * 2013-12-19 2016-10-05 Hill's Pet Nutrition, Inc. Method for determining spoilage of high protein foods
WO2015160234A1 (en) * 2014-04-17 2015-10-22 N.V. Nutricia Composition for brain improvement
BR112017007066A2 (pt) * 2014-10-10 2017-12-12 Nestec Sa composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade
RU2668575C1 (ru) * 2014-12-29 2018-10-02 Хиллс Пет Нутришн, Инк. Пищевая композиция и способ её применения
US20160367509A1 (en) * 2015-06-22 2016-12-22 Nestec Sa Compositions and methods for enhancing neurogenesis in animals
CN105602998A (zh) * 2016-01-18 2016-05-25 青岛哈拿生物科技有限公司 一种水溶性天然一氧化氮的制作方法及应用
EP3463321A1 (en) * 2016-05-27 2019-04-10 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
BR112019004055A2 (pt) * 2016-09-29 2019-05-21 Nestec S.A. ácidos graxos ômega 3, nenhum composto liberador e vitamina b12 como neuroprotetor em pacientes sem demência
KR20190124785A (ko) * 2017-03-18 2019-11-05 스티븐 엠. 맥개러 칸나비디올산을 포함하는 반려동물 식품
BR112019017949A2 (pt) * 2017-04-11 2020-05-19 Nestle Sa níveis de ácidos graxos ômega-3 e vitamina d para identificar e atenuar o envelhecimento cognitivo em indivíduos
JPWO2022191184A1 (pt) * 2021-03-08 2022-09-15

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750572A (en) * 1993-12-14 1998-05-12 Prospa B.V. Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
US20030073747A1 (en) * 2001-10-12 2003-04-17 Gross Steven S. Reversing or preventing premature vascular senescence
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US20070060651A1 (en) * 2005-08-26 2007-03-15 Nestec S.A. Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2018A (en) * 1841-03-26 Joseph francis
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
EP0810829B1 (en) 1995-02-23 2000-04-12 Novartis Nutrition AG Amino acid compositions and use thereof in clinical nutrition
CA2185983C (en) * 1996-09-19 2004-04-13 Wie-Jong Kwak Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
CN1370044A (zh) * 1999-06-14 2002-09-18 亨利福特保健系统公司 用于诱导神经发生的氧化氮供体
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
US20040043013A1 (en) * 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20050002992A1 (en) 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
DE60220899T2 (de) 2001-03-23 2008-03-13 Ajinomoto Co., Inc. Mittel gegen stressinduzierte krankheiten
DE10131516B4 (de) 2001-07-02 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Steuereinheit zur Flussregulierung
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
EP1605781A1 (en) 2003-03-18 2005-12-21 Novartis AG Compositions comprising fatty acids and amino acids
MXPA05013755A (es) 2003-07-03 2006-03-08 Hills Pet Nutrition Inc Composiciones y metodos para disminuir el deterioro relacionado con la edad en las actividades mentales en los animales de compania.
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
EP1665940A4 (en) * 2003-09-02 2011-01-19 Bbk Bio Corp DIETETIC FOODSTUFF
EP1698685A4 (en) 2003-12-22 2008-12-03 Wakunaga Pharma Co Ltd FAT COMPOSITION
US20060002985A1 (en) 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
WO2006071919A2 (en) 2004-12-29 2006-07-06 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
AU2005322887B2 (en) 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP2008526214A (ja) 2004-12-30 2008-07-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 発育期の動物の生活の質を高めるための方法
CN1810257A (zh) * 2005-05-26 2006-08-02 钟健琳 活脑素口服液
EP1908001A1 (en) 2005-06-30 2008-04-09 Koninklijke Philips Electronics N.V. Method and system for selection of information
KR20130101596A (ko) 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
CN101277739B (zh) 2005-09-30 2013-01-02 雀巢技术公司 用于增强认知功能的方法和组合物
US20090286879A1 (en) 2005-12-02 2009-11-19 Kiyoshi Hashizume Preventive or Therapeutic Drug for Alzheimer-Type Dementia
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
HUE040002T2 (hu) * 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
CN101820754A (zh) 2007-10-04 2010-09-01 雀巢产品技术援助有限公司 用于增强认知功能的组合物与方法
EP2939314B1 (en) 2012-12-31 2018-08-29 Mitel Networks Corporation Interface adapter

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750572A (en) * 1993-12-14 1998-05-12 Prospa B.V. Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US20030073747A1 (en) * 2001-10-12 2003-04-17 Gross Steven S. Reversing or preventing premature vascular senescence
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US20070060651A1 (en) * 2005-08-26 2007-03-15 Nestec S.A. Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lau et al, "The beneficial effects of fruit polyphenols on brain aging" , Neurobioloy of Aging 26S (2005), S128-S132. *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US11691995B2 (en) 2005-05-27 2023-07-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20100292330A1 (en) * 2007-10-04 2010-11-18 Yuanlong Pan Compositions and methods for enhancing cognitive function
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US11583608B2 (en) 2009-08-21 2023-02-21 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012103049A1 (en) 2011-01-25 2012-08-02 Nestec S. A. Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
AU2012209285B2 (en) * 2011-01-25 2016-11-17 Nestec S. A. Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
EP2667882A1 (en) * 2011-01-25 2013-12-04 Nestec S.A. Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
US9320759B2 (en) 2011-01-25 2016-04-26 Nestec S.A Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
EP2667882A4 (en) * 2011-01-25 2014-06-25 Nestec Sa METHODS AND COMPOSITIONS FOR TREATING, LIMITING OR PREVENTING DETERIORATION OF THE VISUAL ANIMAL SYSTEM
US20130324608A1 (en) * 2011-02-18 2013-12-05 Yuanlong Pan Methods and compositions for treating, reducing or preventing damage to the nervous system of animals
EP2675447A2 (en) 2011-02-18 2013-12-25 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
WO2012112340A2 (en) * 2011-02-18 2012-08-23 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
WO2012112340A3 (en) * 2011-02-18 2014-04-17 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
US9713652B2 (en) 2011-02-28 2017-07-25 The University Of North Carolina At Chapel Hill Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
WO2012128982A3 (en) * 2011-03-18 2014-04-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
AU2012231351B2 (en) * 2011-03-18 2016-03-10 Société des Produits Nestlé S.A. Compositions and methods useful for ameliorating age related maladies
US20140004205A1 (en) * 2011-03-18 2014-01-02 Nestec Sa Compositions and methods useful for ameliorating age related maladies
US10010566B2 (en) * 2011-03-18 2018-07-03 NestecSA Compositions and methods useful for ameliorating age related maladies
AT511776A1 (de) * 2011-07-26 2013-02-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
AT511776B1 (de) * 2011-07-26 2014-03-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
US20150265670A1 (en) * 2012-10-30 2015-09-24 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US10369186B2 (en) * 2012-10-30 2019-08-06 Kyowa Hakko Bio Co., Ltd. Method of treating decline in brain function comprising coadministration of citrulline and glutathione
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11311581B2 (en) * 2014-10-22 2022-04-26 Again Life Italia Srl Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
US10471034B2 (en) 2016-12-19 2019-11-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US11129804B2 (en) 2016-12-19 2021-09-28 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10238617B2 (en) 2016-12-19 2019-03-26 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US11602511B2 (en) 2016-12-19 2023-03-14 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10201513B2 (en) 2016-12-19 2019-02-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10660870B2 (en) 2017-08-14 2020-05-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US11571404B2 (en) 2017-08-14 2023-02-07 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10973793B2 (en) 2018-06-20 2021-04-13 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US11833127B2 (en) 2018-06-20 2023-12-05 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Also Published As

Publication number Publication date
BRPI0822238B1 (pt) 2020-03-10
CN105267969A (zh) 2016-01-27
AU2008347177B2 (en) 2014-04-17
AU2008347177A1 (en) 2009-07-16
US20210205373A1 (en) 2021-07-08
US20190030088A1 (en) 2019-01-31
CA2994586A1 (en) 2009-07-16
CA2994586C (en) 2020-07-21
US20170157182A1 (en) 2017-06-08
BRPI0822238A2 (pt) 2015-06-30
CN101909632A (zh) 2010-12-08
EP2224930A1 (en) 2010-09-08
BRPI0822238B8 (pt) 2021-05-25
WO2009088433A1 (en) 2009-07-16
US10111911B2 (en) 2018-10-30
JP2011508773A (ja) 2011-03-17
JP5979816B2 (ja) 2016-08-31
RU2010132637A (ru) 2012-02-10
ES2586757T3 (es) 2016-10-18
ES2773928T3 (es) 2020-07-15
RU2500402C2 (ru) 2013-12-10
EP3058942B1 (en) 2019-12-04
MX337760B (es) 2016-03-17
EP3058942A1 (en) 2016-08-24
CA2709660C (en) 2018-06-05
US10973859B2 (en) 2021-04-13
ES2773928T5 (es) 2023-06-28
EP2224930A4 (en) 2011-06-22
EP3058942B2 (en) 2023-03-22
EP2224930B1 (en) 2016-06-15
CA2709660A1 (en) 2009-07-16
US11951137B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
US11951137B2 (en) Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
AU2016202685B2 (en) Compositions and methods for enhancing cognitive function
CA2987033C (en) Compositions and methods for enhancing neurogenesis in animals
AU2010293065B2 (en) Compositions and methods for enhancing cognitive and related functions in animals

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PAN, YUANLONG;REEL/FRAME:026591/0019

Effective date: 20100330

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION